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1. Introduction 
Malignant melanoma, once disseminated, is a malignant neoplasm extremely resistant to 
conventional anticancer treatment, such as chemo or radiation therapies. Therefore, new 
therapeutic strategies are under investigation as, for instance, immunotherapy, gene therapy 
or so called targeted therapy. Proteasome appears as one of these new possible targets. 
The ubiquitin proteasome pathway is a complex multicatalytic system specialized in the 
degradation of proteins of intracellular origin, unlike lysosomes that are specialized in the 
degradation of proteins of extracellular origin. 
Many of the proteins degraded by the proteasome are molecules involved in cell 
proliferation and apoptosis, such as cyclins and cyclin dependent kinases, the proapoptotic 
protein p53 or the nuclear transcription factor NFkappaB. It has been demonstrated that 
inhibition of proteasome induces cell death, more strongly in neoplastic cells than in normal 
cells, and, even more, that proteasome inhibition sensitizes neoplastic cells to other 
proapoptotic stimulus such as chemo o radiation therapy, probably by the NFkappaB 
pathway. Therefore, the proteasome could be a good target for cells so resistant to apoptosis 
as melanoma cells are. 
We and others have demonstrated that melanoma cells are sensitive in vitro to Bortezomib  
and other proteasome inhibitors, that are able to decrease melanoma cell viability, to induce 
a reduction in cell proliferation rate and a cell cycle arrest and to trigger apoptotic cell death 
through both caspase dependent and independent pathways.  
Bortezomib is a commercially available proteasome inhibitor, mainly used for the treatment 
of multiple myeloma and other malignant hematological disorders. Although the only 
published phase II clinical trial using single agent Bortezomib in patients with advanced 
melanoma yielded disappointing results, the potential use of proteasome inhibitors for the 
treatment of metastatic melanoma patients is still under assessment. Based on the 
knowledge of the physiological role of the proteasome system and on preclinical studies, 
employment of proteasome inhibitors in combined therapies seems the best way to afford 
the use of these compounds for advanced melanoma treatment.  
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One of the first drugs employed to this aim was Temozolamide, a chemotherapeutic agent 
that has shown to exert an antitumour effect in a synergic manner when administrated with 
Bortezomib in melanoma animal models. A phase I clinical trial combining Bortezomib and 
Temozolamide that enrolled 19 patients with advanced malignant melanoma has been 
recently published. Although the study has been designed to define phase II dose schedule, 
some limited results (partial response, disease stabilization) have been observed. 
Other multiple combinations containing proteasome inhibitors have been tested in both in 
vitro and in vivo pre-clinical studies. Some of the therapies that have been shown to 
synergize with proteasome inhibitors against melanoma cells are several chemotherapeutic 
agents, calpain inhibitors, interferon, tyrosin-kinase inhibitors, different types of cell 
mediated immunotherapy, etc. As proteasome inhibitors are drugs with pleiotropic effects 
on proliferation and suppression of apoptosis, cell invasion and angiogenesis, multiple 
pathways have been proposed to explain how proteasome inhibition can reduce or avoid 
tumor growth, but ultimate mechanisms remain unclear. In that sense, a great research 
effort is necessary to elucidate the molecular basis of the proteasome inhibitors action on 
melanoma cells in order to better design combined therapeutic strategies. We hope that in 
the future one or more of these or other possible combinations will reach successfully the 
clinical setting.  
Finally, a new promise on the employment of proteasome inhibitors for the treatment of 
metastatic melanoma, are the second generation proteasome inhibitors. They include the 
peptide boronic acid analogs MLN9708 and CEP-18770, the peptide epoxyketones carfilzomib 
and PR-047, and the beta-lactone compound NPI-0052, all of which show a potent in vitro 
proteasome inhibitory activity. They differ in enzyme binding kinetics, which might affect 
their pharmacological properties, efficacy and toxicity. All these features will define their 
future clinical use. 
In the present chapter we will review the structure and function of the proteasome, the role 
of proteasome inhibitors as anti-cancer agents and the current status of preclinical and 
clinical knowledge about the potential use of proteasome inhibitors for metastatic melanoma 
treatment. 
2. The proteasome 
The ubiquitin proteasome pathway is a complex multicatalytic system specialized in the 
degradation of proteins of intracellular origin (Voorhees 2006). Protein synthesis and protein 
degradation are important processes in cellular homeostasis that ensure maintenance of 
protein regulation (Gallastegui 2010). Nevertheless, the concept of protein turnover is quite 
new. At the beginning of the last century, body proteins were viewed as essentially stable 
constituents, and diet proteins were believed to function primarily as energy-providing 
products, which were independent from the structural and functional proteins of the 
organism. The discovery of the lysosome, as one of the compartments for cell protein 
processing, along with other experiments that were carried out at the same time, have 
strengthened the notion that cellular proteins are indeed in a constant state of synthesis and 
degradation (Ciechanover 2010). However, proteolysis in lysosomes is a nonspecific process. 
In higher eukaryotes, only membrane-associated proteins and alien proteins captured 
during endocytosis (viral, bacterial, etc.) are destroyed in lysosomes. Degradation of the vast 
majority (80-90%) of intracellular proteins is realized by the proteasome (Sorokin 2009).  
The proteasome is a large cylindrical particle consisting of at least 33 subunits, with a total 
molecular weight of approximately 2.5 MDa. There are several variants of the proteasome 
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that perform slightly different functions. For example, cells of the immune system contain a 
particular form of the proteasome, the immunoproteasome, that produces peptides for 
display at the cell surface (Schrader 2009). The peptides generated by the 
immunoproteasome are not subjected to further degradation by cell peptidases and are used 
for antigen presentation (Sorokin 2009). The version of the proteasome that is found in all 
cells and is responsible for the specific degradation of regulatory proteins and the removal 
of damaged proteins is called the 26S proteasome. The 26S proteasome is composed of a 20S 
core particle capped by two 19S regulatory particles at both ends (Fig 1). The 20S core 
particle is composed by four heptameric rings, which are assembled to form a cylindrical 
structure. The outer two rings are made of α subunits, and the inner two rings are composed 
of β subunits, which contain the proteolytic active sites in a central cavity. The degradation 
chamber can be reached through a channel that runs along the long axis of the core particle. 
The entrance to the channel is narrow, such that folded proteins must be at least partially 
unfolded before they can be translocated into the 20S core particle and degraded. The 19S 
regulatory particle is composed of at least 19 subunits arranged into two subcomplexes: the 
lid and the base. (Schrader 2009). 
Ubiquitin is a 76-amino-acid-residue protein. It is highly conservative in eukaryotes, but is 
absent in bacteria and archaea. In eukaryotes, several genes encode ubiquitin. Activation of 
ubiquitin requires processing by so called deubiquitinating enzymes (Sorokin 2009). 
Proteins targeted for degradation by the 26S proteasome are first “labeled” by covalent 
linkage of a polyubiquitin chain, via a three-step cascade mechanism utilizing the following 
three enzymes: E1, the ubiquitin-activating enzyme, E2, the ubiquitin-carrier protein, and 
E3, the ubiquitin-protein ligase. Successive conjugation of ubiquitin moieties generates a 
polyubiquitin chain. A polyubiquitin chain consists at minimum of four molecules. These 
polyubiquitinated substrates are recognized by the 26S proteasome and rapidly broken 
down into short peptides. One important function of the 19S regulatory particle is to 
recognize ubiquitinated proteins and other potential substrates of the proteasome. A second 
function of the 19S regulatory particle is to open an orifice in the α-ring that will allow entry 
of the substrate into the proteolytic chamber. Also, since a folded protein would not be able 
to fit through the narrow proteasomal channel, it is assumed that the 19S particle unfolds 
substrates and inserts them into the 20S core particle. Both the channel opening function and 
the unfolding of the substrate require metabolic energy, and indeed, the base of the 19S 
regulatory particle contains six different ATPase subunits. Following degradation of the 
substrate, short peptides derived from the substrate are released, as well as reusable 
ubiquitin (Fig. 1) (Ciechanover 2010, Kim 2011). This process has been named the 
“ubiquitin-dependent degradation of protein” (Sorokin 2009). 
Substrates for this non-lysosomal protein degradation pathway include misfolded and 
defective proteins, as well as others that are selectively polyubiquitin-tagged and targeted 
for degradation by the ubiquitin-proteasome system (Potts 2010). Proteins differ greatly 
from each other in lifetime, and the lifetime of protein molecules in an organism depends on 
their role. So, some structural proteins can remain unchanged for many years, whereas 
regulatory proteins are frequently required only for a few minutes to trigger a certain 
process and after completing their function they should be destroyed. Moreover, in the 
course of time, cells accumulate a large amount of aberrantly folded and oxidized protein 
that should be also eliminated. The proteasome is the basis of a complex multicomponent 
cellular machine for getting rid of these unwanted cell proteins (Sorokin 2009).  
Proteasomes in eukaryotic cells are localized both in the cytoplasm and in the nucleus. 
Nuclear/cytoplasmic distribution of proteasomes seems to be tissue-specific. The 
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distribution of proteasomes between the cytoplasm and the nucleus also changes 
remarkably during embryogenesis. In spermatozoids and ovules, proteasomes are 
concentrated in the cytoplasm, at early stages of subdivision they translocate to the nucleus, 
and by the blastocyst stage the intracellular localization of proteasomes is close to their 
distribution in adult somatic cells. Besides, intracellular distribution of proteasomes changes 
dynamically in accord with the cell cycle phase. Proteasomal degradation of cyclins in the 
nucleus is a necessary condition for the normal course of the cell cycle (Sorokin 2009). 
During the last years, experimental data have pointed about the existence of deviations from 
the classical protein degradation pathway. The vast majority of examples of non-classical 
proteasomal degradation are associated with the ubiquitin-independent degradation of 
proteasome substrates. Some of the proteins that can undergo ubiquitin-independent 
degradation are ornithine decarboxylase, p21, p53 and oncosupressive Rb proteins (Sorokin 
2009). 
 
 
Fig. 1. The ubiquitin-proteasome pathway: The scheme shows the main steps of the 
ubiquitin-proteasome pathway in eukaryotic cells. First, the ATP consumption is needed for 
the binding of ubiquitin (Ub) with the ubiquitin activating enzyme (E1). Second, the 
ubiquitin-carrier protein (E2) takes the ubiquitin molecule from E1. Third, ubiquitin 
molecule is transferred from the E2 to the ubiquitin-protein ligase (E3). Fourth, the target 
proteins bind up to four molecules of ubiquitin. Fifth, the proteasome recognizes the protein 
and finally the protein is degraded by the catalytic core 20S, releasing free molecules of 
ubiquitin and digested peptides 
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In addition, recent emerging evidences suggest the existence of many other non-proteolytic 
functions of both the proteasome and ubiquitin. Non-proteolytic functions of proteasome 
include DNA repair, transcription initiation and transcription elongation. Ubiquitin has 
even more diverse non-proteolytic functions, such as membrane trafficking, protein kinase 
activation, DNA repair, and chromatin remodelling. The relationship of non-proteolytic 
functions between proteasome and ubiquitin is not clear. (Kim 2011, Kwak 2011, Livnat-
Levanon 2011).  
The discovery that ubiquitin modification plays a role in routing proteins to the 
lysosome/vacuole and that modification by specific and unique ubiquitin-like proteins 
controls autophagy demonstrated that the two distinct proteolytic systems, the lysosomes 
and the proteasome, communicate with one another (Ciechanover 2010).  
With the many processes and substrates targeted by the ubiquitin pathway, it is not 
surprising to find that aberrations in the system underlie, directly or indirectly, the 
pathogenesis of many diseases (Ciechanover 2010). 
3. Proteasome inhibitors as anticancer agents 
In addition to providing a mechanism for cellular protein quality control, the ubiquitin-
proteasome pathway facilitates essential cell functions ranging from antigen processing to 
signal transduction, cell cycle control, proliferation, differentiation, angiogenesis and 
apoptosis. Thus, besides involving in normal cellular functions and homeostasis, the 
alteration of proteasomal activity contributes to the pathological states of several clinical 
disorders including inflammation, neurodegeneration and cancer. These critical roles, 
together with the ubiquitious nature of the proteolytic 20S core particle, suggest multiple 
potential applications for proteasome inhibition for several pathological conditions such as 
inflammation / autoimmune diseases and cancer therapy (Potts 2010, Chen Current Protein 
2010).  
Many of the proteins degraded by the proteasome are molecules involved in cell 
proliferation and apoptosis, such as cyclins and cyclin dependent kinases, the proapoptotic 
protein p53, members of the Bcl2 family, the nuclear transcription factor NFkappaB, etc. 
Thus, the inhibition of proteasome activity could have important downstream consequences 
that can be used to advantage in tumor cells. It has been demonstrated that inhibition of the 
proteasome induces cell death in both normal and neoplastic cells, that cancer cells possess 
elevated levels of proteasome activity and are more sensitive to proteasome inhibitors than 
normal cells and, even more, that proteasome inhibition sensitizes neoplastic cells to other 
proapoptotic stimulus such as chemo o radiation therapy, probably by the NFkappaB 
pathway. These and other findings provided strong rationale for targeting the proteasome 
for the treatment of cancer (Voorhees 2006, Potts 2010, Chen 2010b). 
One of the principal actions of proteasome inhibitors are the regulation of cell cycle control 
molecules. Ubiquitin-dependent proteolysis mediates the normal turnover of p53, the 
guardian of human genome. Consequently, proteasome inhibition leads to p53 accumulation 
and subsequently induces the transcription of cyclin-dependent kinase inhibitor p21. 
Proteasome inhibition also induces p53 phosphorylation. Some studies reveal that the 
ubiquitin-proteasome system is responsible for the degradation of p21 and p27, both of 
which are important cell cycle regulators whose expression are down-regulated in various 
malignancies. So, an important biologic effect of proteasome inhibitors is the accumulation 
of p27 (Voorhees 2006, Wu 2010, Chen 2010b). 
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Another main action of proteasome inhibitors is the regulation of pro- and anti-apoptotic 
proteins. The execution of apoptosis is largely governed by opposing activities of pro-(Bax, 
Bak, Bik,Bim, Bad, Bid, HRK, NOXA, PUMA, and BNIP3) and antiapoptotic (Bcl-2, Bcl-xL, 
Bcl-w, A1, and Mcl-1) members of the Bcl-2 family. Altogether, such group of proteins 
regulates mitochondrial membrane permeability, cytochrome C release, generation of 
reactive oxygen species, and caspase activation. Proteasome inhibition has been shown to 
favor balance to pro-apoptotic signaling. Therefore, proteasome inhibitors block the 
degradation and upregulate the expression of Bax, Bik, Bim, and NOXA. Proteasome 
inhibition also activates transcription of PUMA and promotes Mcl-1 cleavage. Moreover, 
proteasome inhibitors downregulate the expression of a class of proteins, known as 
inhibitors of apoptosis (IAPs), that suppresses the effector caspases. To this end, proteasome 
inhibitors reduce the expression of several IAPs, including cIAP-1, XIAP and survivins 
(Voorhees 2006, Wu 2010, Chen 2010b) 
As above mentioned, proteasome inhibitors have been shown to synergize with several 
chemotherapeutic drugs inducing apoptosis of malignant cells. This action has been 
mainly explained by their inhibitory effect on NFκB activation. NFκB is a heterodimeric 
transcription factor, mostly composed of 65 and 50 kDa subunits, which is prevented from 
translocation into the nucleus through association with a family of inhibitory proteins 
called IκB. Upon stimulation through several factors (basically chemokines and cytokines, 
such as TNFα, free radicals, ultraviolet radiation or bacterial components) the IκB is 
phosphorylated, ubiquitinated and subsequently degraded in the 26S proteasome. Then, 
free NFκB translocates into the nucleus, where it activates transcription of genes whose 
products can inhibit apoptosis by mediating cellular survival responses. This signal 
pathway has been called “canonical” NFκB activation, in front of “non-canonical” or 
different mechanisms of activation of NFκB. As NFκB also regulates angiogenesis, cell 
cycle control, adhesion and migration, strategies employed by malignant tumors to evade 
antitumoral therapies include upregulation of NFkB. Thus, on the one hand, many tumor 
cells, in contrast to their normal counterparts, show constitutive activation of NFkB. On 
the other hand, treatment of malignancies with radiation therapy or some cytostatic 
compounds, such as anthracycline drugs, leads to induced activation of NFkB. The latter 
mechanism is considered a major cause for the development of inducible chemoresistance. 
Thus, strategies to inhibit NFkB in malignant tumors are considered a worthwhile 
addition to the current therapeutic options. One way to indirectly inhibit the NFκB 
pathway is via the inhibition of the 26S proteasome. Lack of degradation of IκB induces 
increased levels of the IκB inhibitory subunit that prevents NFκB from translocation into 
the nucleus, and subsequently activation of anti-apoptotic and survival signals. In 
addition, the proteasome has also shown to have a role in the “non-canonical” NFκB 
activation. Consequently, proteasome inhibitors are strong potential substances for NFκB 
blockade of and chemosenzitation of cancer cells (Voorhees 2006, Yang 2006, Testa 2009, 
Amschler 2010). 
Thus, proteasome inhibitors induce tumoral cell-cycle arrest and apoptosis, inhibit cell-
adhesion, migration and release of angiogenic factors and sensitize malignant cells to pro-
apoptotic stimulus such as chemotherapeutic agents or radiation therapy (Amschler 2010, 
Testa 2009, Wu 2010, Chen 2010b) 
Other important actions of proteasome inhibitors are the accumulation of misfolded 
proteins and endoplasmic reticulum stress, the induction of oxidative stress, the down 
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regulation of the PI3K/AKT pathway, the activation of bone morphogenetic protein 
signaling, the repression of global protein translation, the immunosensitization of cancer 
cells to the cytotoxicity of lymphocytes, etc. In addition, proteasome inhibitors can induce 
cytoprotective responses that attenuate their antitumor efficacy, such as upregulation of 
heat-shock proteins, induction of macroautophagy, or activation of some other prosurvival 
signaling pathways, even NFκB.  In summary, the specific effects and precise mechanism of 
action of proteasome inhibition in malignancy remain unclear and are subject to further 
investigation (Rajkumar 2005, Voorhees 2006, Wu 2010). 
There are five main types of proteasome inhibitors that bind either reversibly or irreversibly 
to the active enzyme sites in the 20S proteasome, primarily the chymotrypsin-like site, thus 
inhibiting their proteolytic function. These types include peptide vinyl sulfones, peptide 
boronates, peptide epoxyketones (Epoxomycin and Eponomycin) and -lactones (Lactacystin 
and derivatives). Only a few compounds have progressed to clinical development, however, 
with others deemed unsuitable owing to metabolic instability, potency issues or lack of 
specificity (Dick 2010). 
Bortezomib (PS-341) is the first-in-class proteasome inhibitor that reached human clinical 
use. Other first-in-class proteasome inhibitors, not available for clinical use in humans (such 
as MG-132, ALLN, Lactacystin, Epoxomicin, etc), have been extensively employed in the 
experimental setting in order to better understand the ubiquitin-proteasome pathway and 
the potential clinical use of the whole group. Bortezomib is a dipeptidyl boronic acid analog 
that reversibly inhibits the 26S proteasome by binding to N terminal threonine residues in 
the active site of the chymotrypsin-like catalytic región. It has been approved for the 
treatment of multiple myeloma and relapsed mantle cell lymphoma. However, it has 
generally been ineffective as monotherapy for the treatment of a wide variety of solid 
tumors. Bortezomib can overcome or reverse chemoresistance and increase sensitivity to 
chemotherapeutic agents, including Melphalan, Doxorubicin, Mitoxantrone, and to 
Dexamethasone.  Such combinations have been approved for relapsed or newly diagnosed 
multiple myeloma. Moreover, combinations of Bortezomib and novel targeted therapies 
may act synergistically to increase antitumor activity and overcome specific cellular 
resistance and/or antiapoptotic mechanisms. Those targeted therapies include protein 
deacetylase inhibitors, kinase inhibitors, farnesyltransferase inhibitors, heat-shock protein 90 
inhibitors, pan-Bcl-2 family inhibitors, and other classes of targeted inhibitors. Based in the 
results of preclinical studies, some early-phase clinical trials combining Bortezomib and 
other targeted therapies are ongoing, basically for the treatment of multiple myeloma 
patients (Voorhees 2006, Testa 2009, Orlowski 2008, Wright 2010 Eisenle 2010). 
In clinical trials of multiple myeloma patients, Bortezomib adverse events have been 
reported in at least 10% of cases. They include anemia, anorexia, constipation, dehydration, 
diarrhea, dizziness, fatigue, headache, limb pain, nausea, neutropenia, peripheral 
neuropathy, pyrexia, rash, thrombocytopenia, vomiting, and weakness. Thrombocytopenia 
and neuropathy are probably the most limiting in the clinic (Orlowski 2008). 
With the validation of the proteasome as a target for cancer therapy, interest has focused on 
the possibility that proteasome inhibitors other than Bortezomib could offer some 
advantages. Various second-generation agents are now in development. Among peptide 
boronic acid analogs, two new molecules have to be mentioned. MLN9708, which 
hydrolyses immediately in plasma to MLN2238, is a reversible inhibitor of the 
chymotrypsin-like subunit of the 20S proteasome that is distinct from Bortezomib in having 
a substantially shorter dissociation half-life. CEP-18770 (Cephalon) is a P2 threonine boronic 
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acid that is another reversible inhibitor, primarily of the chymotrypsin-like activity of the 
proteasome. Two compounds in the peptide epoxyketone class are being developed. 
Carfilzomib (formerly PR-171) is an irreversible inhibitor of the chymotrypsin-like activity 
of the proteasome, and PR-047 is an orally bioavailable analog of Carfilzomib, again being 
an irreversible inhibitor of the β5 subunit. Finally, several natural compounds have been 
identified as inhibitors of the proteasome. Marizomib (NPI-0052, or salinosporamide A), is a 
β-lactone compound derived from the marine bacterium Salinospora tropica; like 
Carfilzomib and PR-047, it is also an irreversible inhibitor of the β5 subunit. Given their low 
nanomolar IC50 values for the β5 subunit, Bortezomib and the second-generation inhibitors, 
all represent very effective inhibitors of proteasome activity. NPI-0052 also has a low 
nanomolar IC50 for the trypsin-like (β2) subunit. Two second-generation agents have 
entered phase I trials: NPI-0052 and Carfilzomib. Both, unlike Bortezomib, bind irreversibly 
the proteasome, abrogating one mechanism of recovery from proteasome inhibition, such as 
release of the target by the drug. Preclinical studies have shown that both at least partially 
overcome Bortezomib resistance in vitro. Moreover, in a number of models, including 
multiple myeloma and chronic lymphocytic leukemia, these inhibitors have shown 
enhanced potency compared with Bortezomib, suggesting they may have a broader 
spectrum of activity. Early results from phase I studies of Carfilzomib indicate that it is well 
tolerated, even on a dose intense schedule, and may have less neurotoxicity than 
Bortezomib. Evidence of antitumor activity is being seen in multiple myeloma and 
Waldenstron’s macroglobulinemia, including in myeloma patients with previously 
Bortezomib-refractory disease.  In phase I clinical trials employing Marizomib for patients 
with leukemia, lymphoma and other solid tumors, Marizomib did not appear to induce the 
limiting toxicities associated with Bortezomib, such as peripheral neuropathy, neutropenia 
and thrombocytopenia, in spite of eliciting levels of proteasome inhibition that equal or 
exceed those produced by Bortezomib. Anti-tumor activity was also seen in multiple 
myeloma patients previously treated with Bortezomib.  Marizomib phase I clinical trials 
combining second generation proteasome inhibitors with other targeted therapies, as for 
instance Marizomib plus Vorinostat (a hystone deacetilating agent), have been initiated. 
Second-generation proteasome inhibitors might address some of the key issues associated 
with Bortezomib, such as improving the efficacy of proteasome inhibition in solid tumors, 
and limiting therapy-associated peripheral neuropathy. Combinatory therapy employing 
two different proteasome inhibitors, such as Bortezomib and Marizomib has also been 
proposed. Extensive clinical investigation of the second-generation inhibitors will be 
required, however, to determine whether the pharmacologic differences between these 
agents and Bortezomib will result in differences in efficacy and safety in patients. (Orlowski 
2008, Testa 2009, Einsele 2010, Dick 2010, Potts 2010, Bettignies 2010, Berkers 2010, Potts 
2011).  
Finally, another interesting concept about the use of proteasome inhibitors as anticancer 
agents is the role of the feedback regulation of proteasome gene expression as a possible 
mechanism of proteasome inhibitors resistance in solid tumors. The proteasome can be 
regulated at different levels. The 26S proteasome is composed of 33 distinct subunits each 
encoded by a different gene. Regulation of proteasome gene expression is another important 
mechanism that controls proteasome homeostasis. The discovery of feedback regulation of 
proteasome gene expression has several important implications in cancer therapy that 
targets the proteasome. First, it provides a clue to understand the cause of proteasome 
overexpression often-detected in cancers. Second, the feedback mechanism may contribute 
www.intechopen.com
 
Targeting the Proteasome in Melanoma 
 
469 
to drug resistance in cancer therapy. The feedback induction, which normally occurs only 
when the proteasome activity is suppressed, may become constitutively active in cancer 
cells. As already mentioned, Bortezomib is the only proteasome inhibitor in clinical use. 
Although this drug has shown promising results in the treatment of multiple myeloma and 
mantle cell lymphoma it has limited efficacy in other cancer types. Whereas the 
compromised efficacy of Bortezomib by the feedback mechanisms may still be sufficient to 
kill myeloma tumor cells, it may not be strong enough to be effective in other cancers, 
especially solid tumors. Thus, the feedback pathway presents a potential target for cancer 
therapy. To date, proteasome inhibitors attacking the catalytic sites of the proteasome are 
the only tool to reduce the proteasome activity. However, knockdown of individual 
proteasome genes combined with proteasome inhibitors may present a promising 
alternative in cancer therapy. Further investigation of these mechanisms will provide more 
choices for proteasome-targeting cancer therapy (Xie 2010). 
4. Melanoma and proteasome inhibitors 
Cutaneous melanoma is the most aggressive form of skin cancer. Its treatment is based on 
early detection and surgical excision. Once in an advanced stage, metastatic melanoma 
presents a very poor prognosis as it becomes resistant to conventional anticancer treatments, 
such as chemo or radiation therapies. At the moment, the methylating agent Dacarbazine is 
still the standar therapy for metastatic melanoma allowing clinical objective responses in 
only 10-20% of patients, with a complete response rate of less than 5%, and a short median 
response duration of 4-6 months. Therefore, new therapeutic strategies are under 
investigation as, for instance, immunotherapy or so called targeted therapy (Ibrahim 2009, 
Lutzky 2010).  
Some of the mechanisms related to the aggressive behavior of melanoma cells are  
1) constitutive activation of growth factor receptors (c-Kit, PDGFR-α, EGFR), 2) constitutive 
activation of the MAP-kinase pathway (RAS/RAF/MEK/ERK), 3) constitutive activation of 
the PI3K/AKT pathway (partially due to loss, mutation, or epigenetic silencing of PTEN 
tumor suppressor gene), 4) constitutive activation of transcription factor NFκB,  
5) disregulation (deletions, silencing, mutations) of proteins involved in cell cycle control 
(CDKN2A/CDK4/CCND1), 6) impairment of transcriptional activities of proapoptotic 
protein p53 and 7) overexpression of antiapoptotic Bcl-2 protein family (Fecher 2007, Rother 
2009, Nathanson 2010). Besides these mechanisms, directly involved in cell proliferation and 
survival, melanoma cells also employ other strategies that allow them to invade and migrate 
(p.e. aberrant expression of adhesion molecules) (Kuphal 2005, Abdullah 2010, Braeuer 
2011), to grow (p.e.secretion of angiogenic factors) (Basu 2009, Ria 2010), and to escape the 
immune system control (Gajewski 2007). Theoretically, any molecule involved in hot points 
of this altered cell machinery could be a good target for melanoma treatment. 
Up to now, targeted therapies that have reached the best results on the clinical setting are 
specific inhibitors of BRAF (PLX4032) in melanomas with the V600E BRAF mutation, c-Kit 
inhibitors in melanomas harboring c-Kit mutations (Davies 2010) and anti-CTLA-4 
antibodies, such as Ipilimumab or Tremelimumab, that overcome the mechanisms of 
immunotolerance (Boasberg 2010). Although the introduction of these drugs has been a 
great advance for the treatment of patients with metastatic melanoma, this only represents 
the end of the very beginning. First, despite impressive clinical responses to PLX4032 
treatment, most responsive patients ultimately relapse because of acquired resistance. 
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Second, melanomas with c-Kit mutations constitute only a very low percentage of the whole 
group of metastatic melanomas and, from what we know about other neoplasms with c-Kit 
mutations, relapse because of acquired resistance will also occur. Third, we continue 
without a good alternative for melanoma patients with tumors presenting a molecular 
profile different to BRAF/V600E or c-Kit mutations. And, finally, we lack biomarkers to 
identify subgroups of patients that will respond to anti-CTLA-4 therapy (Flaherty 2010, 
Shepherd 2010, Robert 2009).  
For most authors, a possible therapeutic approach to avoid drug resistance developed in 
patients treated with single agent therapy is the use of combinatory treatments that 
simultaneously target different cellular pathways. In this context, proteasome inhibitors, 
that have pleiotropic effects on proliferation, survival, migration, invasion and angiogenesis, 
and that can synergize with several other drugs or therapies, appear as a good tool for 
metastatic melanoma treatment (Tawbi 2009).  
4.1 Preclinical evidences of usefulness of proteasome inhibitors in melanoma 
4.1.1 Effect of single-agent proteasome inhibitors on melanoma cells 
First observations about the in vitro effect of proteasome inhibitors on proliferation and 
survival of melanoma cells were published by our group and others during 2004-08. These 
studies demonstrated that several different proteasome inhibitors (Bortezomib, that was the 
only one used in clinical practice, and ALLN, MG-132 and Epoxomicin, that were 
exclusively used in experimental studies) were able to decrease the viability of melanoma 
cell lines by inhibiting their proliferation, causing cell cycle arrest and inducing apoptotic 
cell death by caspase-dependent and -independent mechanisms, AIF related (Fernandez 
2005, Qin 2005, Nikiforov 2007, Sorolla 2008).  
Investigation of underlying molecular mechanisms to the effect of proteasome inhibitors in 
melanoma cells indicated that Bortezomib-mediated release of mitochondrial death inducers 
is not preceded by a significant cleavage of Bid nor down-regulation of apoptotic factors 
frequently related with the NFκB pathway (Bcl-2, Bcl-xL, XIAP, FLIP, TRAF-2), all 
previously associated with melanoma chemoresistance (Fernandez 2005). Comparing 
benign melanocytes with melanoma cells and other neoplastic cells, these studies also 
showed that proteasome inhibitors have the feature of promoting a dramatic induction of 
the proapoptotic protein NOXA in a tumor cell-restricted manner (Fernandez 2005, Qin 
2005). The induction of NOXA by proteasome inhibitors was P53 (Qin 2005), HIF-1 and E2F-
1 independent but directly dependent on the oncogene c-MYC. Thus, c-MYC appeared as a 
direct modulator of NOXA, essential for the regulation of NOXA by the proteasome in 
neoplastic cells, providing a molecular explanation for the preferential selectivity of 
proteasome inhibitors toward tumor cells (Yerlicava 2008, Fuchs 2008). The role of NOXA in 
the response of melanoma cells to Bortezomib was validated in xenograft murine model 
systems (Fernandez 2005, Qin 2005).  
A recent work presented a genome-wide siRNA screen for modulators of cell death induced 
by Bortezomib on colon cancer, cervical cancer and malignant melanoma cells. The authors 
found that a common set of 39 genes was responsible for conferring sensitivity to 
Bortezomib in the different tumor cell types. They causally linked Bortezomib-induced 
apoptosis to the accumulation of ASF1B, MYC, ODC1, NOXA, BNIP3, Gadd45α, p-SMC1A, 
SREBF1, and p53. These results suggested that proteasome inhibition promotes cell death 
primarily by dysregulating MYC and polyamines, interfering with protein translation, and 
disrupting essential DNA damage repair pathways; in summary, leading to the inhibition of 
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multiple homeostatic responses that finally drive tumor cells to engage programmed cell 
death. They considered that such information could be useful to the design of 
pharmacodynamic biomarkers and the application of combination chemotherapy regimens 
containing Bortezomib (Chen 2010a). 
Additional studies of our group and others also showed that antioxidant agents can block 
apoptosis triggered by proteasome inhibition in melanoma and other tumor types 
(Fernandez 2006, Llobet 2008). In detail, the antioxidant compound Tiron completely 
inhibits proteasome-induced apoptosis caused by the boronic acid-based proteasome 
inhibitor Bortezomib, but has no effects on the aldehyde proteasome inhibitors MG-132 and 
ALLN.  Conversely, the antioxidant molecule, called Edaravone, blocks the MG-132 and 
ALLN-induced apoptosis, but does not have significant effects on apoptosis induced by 
Bortezomib. Vitamin C has been also shown to abrogate the ability of Bortezomib to induce 
apoptosis in several other cancer cell lines. (Llobet 2008, Zou 2006). These results indicated 
that different antioxidants are able to block different proteasome inhibitors in a specific way 
and may have important implications for the design of drug mixtures containing 
proteasome inhibitors. 
Finally, Bortezomib-induced endoplasmic reticulum stress and autophagy in melanoma 
cells are other antineoplastic functions of proteasome inhibitors that have become a point of 
great interest in the last few years (Hill 2009, Armstrong 2011). 
4.1.2 In vitro and in vivo melanoma preclinical models about proteasome inhibitor-
based combinatory therapy 
As melanoma is almost universally resistant to chemotherapy and shows a constitutive 
activation of transcription factor NFκB, inhibition of the proteasome seemed a good option 
to overcome melanoma cell chemoresistance.  
One of the experimental studies, that most encouraged the clinical use of combinatory 
therapy containing proteasome inhibitors and chemotherapeutic agents in melanoma, was 
published in 2004. The authors showed that Bortezomib enhanced Temozolamide induced 
growth inhibition of melanoma cells in vitro and in vivo in a xenograft tumor model. Tumor 
growth decrease was related to inhibition of nuclear translocation of NFκB, stabilization of 
p53 and p21 levels and, ultimately, induction of apoptosis. The combination also 
significantly inhibited tumoral angiogenesis when compared with the use of Temozolamide 
alone (Amiri 2004).  Significantly enhanced killing of melanoma cells was also achieved by 
simultaneously triggering production of NOXA (using Bortezomib) as well as reducing Mcl-
1 levels (using Fludarabine) (Qin 2006). 
More recently, another study demonstrated that the proteasome inhibitor Bortezomib led to 
a significant synergistic enhancement of the antitumoral activity of the chemotherapeutic 
agent Camptothecin on melanoma cells. This effect consisted in broader induction of cell 
apoptosis, suppression of cell invasion, as well as inhibition of in vivo metastasis in a murine 
model. A reduced degradation of IkB and, consecutively, a reduced activity of NFκB were 
observed, as expected. The in vivo model allowed to assess the inhibition of nuclear NFkB 
translocation and the induction of melanoma cell apoptosis in pulmonary melanoma 
metastases. In addition Bortezomib exerted pleiotropic and/or off-target effects. These 
effects were, at least in part, independent of proteasome inhibition or independent to NFκB 
inhibition and differed from those induced by the selective IKKb inhibitor, KINK-1. For 
instance, it was found that Camptothecin-induced upregulation of the Bcl-2 family protein 
NOXA was markedly augmented by Bortezomib, whereas KINK-1 achieved a less 
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pronounced increase. Bortezomib also led to a marked increase of the Camptothecin 
induced release of cytochrome C (a critical step in the mitochondrial pathway of apoptosis) 
that was not seen after melanoma cells incubation with KINK-1 (Amschler 2010).  
The second generation proteasome inhibitor Marizonib (NPI-0052 or salinosporamide A) 
seems also to sensitize prostate cancer and malignant melanoma cells to Cisplatinum (Potts 
2011). 
Other agents that showed a synergistic effect on melanoma cells when combined with 
proteasome inhibitors are radiation therapy (Munshi 2004), Geldanamycin and  Geldanamycin 
analogues (that target the Hsp 90 protein chaperone) (Bonvini 2001, Mimnaugh 2004, Banerji 
2009), the Hsp70 inhibitors KNK-437 and Schisandrin-B (Yerlikaya 2010), Mistletoe Lectin-I 
and the PPAR-A agonist Rosiglitazone (Freudlsperger 2007), Gossypol (an inhibitor of the 
anti-apoptotic proteins Mcl-1/Bcl-2/Bcl-xL) (Wolter 2007) and the BH3 mimetic ABT-737 
(inhibitor of Bcl-2/Bcl-X(L)/Bcl-w) (Miller 2009), the cytokines Interferon-alpha (Lesinski 
2008, Lesinski 2009) and IL-29 (Guenterberg 2010),  Bacitracin (a protein disulfide isomerase 
inhibitor) (Lovat 2008),  Decitabine (a demethylating agent) (Halaban 2009),  Fenretinide  
(a synthetic retinoid inducing endoplasmic reticulum stress) (Hill 2009), Evodiamine (Wang 
2010), GRP78-specific subtilase toxin (that inhibits GRP78, a vital unfolded protein response 
mediator) (Martin 2010) and newly developed SMAC-mimetics (Lecis 2010). A combination 
of the new generation proteasome inhibitor Marizomib with histone deacetylase inhibitors 
was also tested in preclinical melanoma models, with not yet published results (Potts 
2011).  
Proteasome inhibition also enhanced the effect of cell-mediated immunotherapies in 
melanoma animal models, such as dendritic cell-based immunization/activation 
(Schumacher 2006) and adoptive transfer of tumor-specific T lymphocytes (Seeger 2010, 
Jazirehi 2011). Nevertheless, some paradoxical responses to this type of approach have been 
observed (Lundqvist 2010).  
Recently, our group showed that a combined exposure to the multikinase inhibitor Sunitinib 
and Bortezomib resulted in a synergistic decrease of cell viability and an increase in caspase 
activation and apoptosis in two Sunitinib sensitive melanoma cell lines (M16 and M17) 
(Yeramian 2011). We demonstrated that constitutive activated PDGFRα and VEGFR2, 
respectively, were the targets of the observed Sunitinib effect.  Proteasome inhibition did not 
show any additive or synergistic effect on Sunitinib resistant cell lines. In Sunitinib sensitive 
cell lines, Sunitinib inhibited Akt phosphorylation in its two residues (Thr 308. Ser 473), 
suppressed the phosphorylation of ribosomal protein p70S6KSer240/244 and 
downregulated the levels of cyclin D1. In addition, Sunitinib partially inactivated ERK in 
M17 but not in M16 cell line because M16 harbored the BRAF/V600E mutation that 
maintains the ERK pathway active despite the complete inactivation of PDGFRα by 
Sunitinib. Moreover, LY294002, a PI3K inhibitor, sensitized melanoma cells to Bortezomib 
treatment, suggesting that down-regulation of phospho-Akt by Sunitinib mediates the 
synergy obtained by Bortezomib plus Sunitinib co-treatment. Altogether, our results suggest 
that melanoma cells harbouring an activated tyrosin-kinase receptor may be clinically 
responsive to pharmacologic receptor tyrosin-kinase inhibition by Sunitinib, and a strategy 
combining Sunitinib and Bortezomib, may provide therapeutic benefit. Moreover, our 
results also highlighted that subgrouping of melanomas by their molecular profile will be 
important in the design of personalized combined therapies containing proteasome 
inhibitors. Different responses to Bortezomib therapy in BRAF wild type or BRAF mutated 
melanoma cells have also lately described by other authors (Armstrong 2011).  
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4.2 Clinical studies employing proteasome inhibitors in patients with metastatic 
melanoma 
Bortezomib is the proteasome inhibitor that has been preferentially clinically evaluated for 
the treatment of metastatic melanoma, as single agent or in combination with conventional 
chemotherapeutic drugs.  
The first phase II clinical trial has employed Bortezomib as single agent administered twice 
weekly for 2 weeks, every 3 weeks at a intravenous dose of 1.5 mg/m2.  The study was 
intended to treat 45 patients, but it was closed after an interim analysis due to early evidence 
of insufficient clinical efficacy. Twenty-seven patients with a median age of 56 years (range, 
32–77 years) were included. Objective responses were not observed. Only 6 patients (22%) 
achieved stable disease. Of these 6 patients, 4 were still stable after 4 cycles of treatment, but 
were removed from the study due to toxicity. The median time to disease progression was 
1.5 months (95% confidence interval, 1.4 –1.6) and the median overall survival was 14.5 
months (95% confidence interval, 9–22). No Grade 4/5 treatment-related toxicities were 
reported. Eleven patients (42%) had Grade 3 toxicities including sensory neuropathy, 
thrombocytopenia, constipation, fatigue, ileus, abdominal pain, and infection without 
neutropenia. After these results, the authors concluded that single-agent Bortezomib was 
not found to be effective in the treatment of patients with metastatic melanoma, and that 
exploration of combination regimens may be warranted (Markovic 2005).  
Based in previous in vitro and in vivo experimental evidence of the existence of a synergic 
effect between Bortezomib and the chemotherapeutic agent Temozolamide on melanoma 
cells (Amiri 2004), a second phase I trial was designed. Objectives included defining a 
maximum tolerated dose for the combination, characterizing biomarker changes reflecting 
inhibition of both proteasome and NFκB activity in blood and tumor samples, and 
characterizing antitumor activity. Nineteen melanoma patients with poor prognostic factors 
(including 17 patients with M1c type metastasis and 10 with raised serum LDH) were 
enrolled onto four escalating dose levels of Temozolomide and Bortezomib. Bortezomib, 1.3 
mg/m2, and Temozolomide, 75 mg/m2, proved to be the maximum tolerated dose. Dose-
limiting toxicities were neurotoxicity, fatigue, diarrhea, and rash. Objective responses 
included only a partial response of 8 months of duration. Three more patients achieved 
stabilization. A significant reduction in proteasome-specific activity in peripheral blood 
mononuclear cells was observed 1 hour after infusion at Bortezomib. Nevertheless, 
consistent effects on NFκB activation could not be detected. Authors gave different 
explanations to this fact including the possibility that Bortezomib acts on melanoma cells 
through other mechanisms such as a c-MYC–dependent increase in NOXA. A phase II trial 
is already in progress (Su 2010).  
Finally, a recent phase II clinical trial has been published about the effect on metastatic 
melanoma patients of the combination of Paclitaxel, Carboplatin, and Bortezomib. This trial 
was based in preclinical studies demonstrating that Bortezomib has anticancer 
additive/synergistic effects when combined with several chemotherapeutic agents, 
including Paclitaxel and Platinum, and the results of a previous phase I trial of this 3-drug 
combination that included patients with metastatic melanoma and other tumor types (Ma 
2007). Bortezomib was administered at a dose of 1.3 mg/m2 intravenously, Paclitaxel at a 
dose of 175 mg/m2, and Carboplatin at an area under the concentration. Seventeen patients 
were enrolled. A median of 4 cycles were administered. Three patients discontinued 
treatment due to persistent grade 4 neutropenia with grade 3 leukopenia or grade 4 
pulmonary embolism. Grade 3 toxicities included neutropenia, leukopenia, thrombocytopenia, 
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and arthralgia. Two partial responses and four stabilization of disease were observed. The 
median progression-free survival was 3.2 months, and the median overall survival was 7.0 
months. The authors concluded that the combination of Paclitaxel, Carboplatin and 
Bortezomib in patients with metastatic melanoma lacks sufficient clinical activity and was 
associated with significant toxicity to warrant further investigation (Croghan 2010). 
Clinical trials of malignant melanoma patients based on combinatory treatments employing 
proteasome inhibitors and therapeutic strategies other than conventional chemotherapy 
have been not published so far. 
Additional phase I clinical trials combining Bortezomib with interferon-alfa (Kendra 2008) 
or with Dacarbazine (Roberts 2006) have also been reported at ASCO meetings. Although 
the primary objective of the trials was to determine the safety, tolerability and dose limiting 
toxicities, the antitumoral activity of the combinations was quite limited and, to our 
knowledge, phase II clinical trials employing these combinatory therapies are not currently 
ongoing. Other two phase I clinical trials employing de second-generation proteasome 
inhibitor, Marizomib, have also been reported at the 2008 and 09 ASCO meetings. 23 and 30 
patients with different tumor types were enrolled, including patients with myeloma, 
lymphomas, leukemias, and solid tumors. Stable disease was induced in one and two 
patients with melanoma, respectively. The toxicity profile was tolerable and dissimilar to 
Bortezomib in spite of reaching higher levels of proteasome inhibition (Aghajanian 2008, 
Townsend 2009). 
5. Conclusion 
In conclusion, biologic properties of proteasome inhibitors and preclinical studies suggested 
that this type of pharmacological agents could be a good therapeutic approach for the 
treatment of many cancer types. However, first human clinical assays employing the first 
commercially available proteasome inhibitor, Bortezomib, demonstrated that this drug is 
quite effective in some hematologic malignancies but not in solid tumors, such as malignant 
melanoma, nor as single agent nor in combination with conventional chemotherapeutic 
products. Nevertheless, multiple preclinical studies, carried out on in vitro or in vivo 
melanoma models, support that proteasome inhibitors could be useful in combinations with 
several targeted therapies or different immunotherapeutic strategies. As we currently know 
that melanoma is a molecular heterogeneous disease, studies designed to increase our 
knowledge about underlying mechanisms to the combined action of proteasome inhibitors 
and other treatments on the different melanoma subtypes are warranted. In this way, we 
could have a rational basis to select those groups of melanoma patients in which proteasome 
inhibitor-based therapy could be a good choice. Finally, second generation proteasome 
inhibitors appear as a chance for the treatment of solid tumors. Probably in the coming years 
we will see to what extent this can be a reality in melanoma. 
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